Published in AIDS Weekly, November 27th, 2006
"This substantial NIH award provides important validation of Argos' pioneering approach to personalized immunotherapy, which may have strong applications not only for HIV, but also for cancer and other infectious diseases," commented Charles Nicolette, VP of Research and Development at Argos and Principle...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.